Protalix (PLX) Reports Presentation of PRX-105 Research on Striatum Splicing Patterns
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Join SI Premium – FREE
Protalix BioTherapeutics, Inc. (AMEX: PLX) report that a paper entitled: "Adaptive alternative splicing correlates with less environmental risk of Parkinsonism," has been published online in the Journal of Neurodegenerative Diseases. The research includes an investigation of the effect of Protalix's PRX-105 on alternative splicing patterns in the striatum, which may confer protection in Parkinson's disease.
PRX-105 is a plant derived version of the human soluble acetylcholinesterase splice variant R (AChE-R) that is in development for several indications, including a biodefense program and an organophosphate-based pesticide treatment program. Building on prior research supporting a role for disrupted alternative splicing in several neurodegenerative diseases, scientists from the Hebrew University of Jerusalem, Israel and Protalix BioTherapeutics investigated splicing patterns in pre-clinical models of Parkinson's disease to determine a possible role of AChE-R in the brain's protective mechanisms.
The research highlights that a splice shift, either inherited or induced by environmental factors (e.g. neurotoxins), from the more common 'synaptic form' of acetylcholinesterase (AChE-S) to the monomeric 'read-through' variant of AChE (AChE-R), is important in conferring protection against Parkinson-like symptoms. Furthermore, intravenous injection with PRX-105 induced a protective gene expression profile in the striatum of the brain.
PRX-105 is a plant derived version of the human soluble acetylcholinesterase splice variant R (AChE-R) that is in development for several indications, including a biodefense program and an organophosphate-based pesticide treatment program. Building on prior research supporting a role for disrupted alternative splicing in several neurodegenerative diseases, scientists from the Hebrew University of Jerusalem, Israel and Protalix BioTherapeutics investigated splicing patterns in pre-clinical models of Parkinson's disease to determine a possible role of AChE-R in the brain's protective mechanisms.
The research highlights that a splice shift, either inherited or induced by environmental factors (e.g. neurotoxins), from the more common 'synaptic form' of acetylcholinesterase (AChE-S) to the monomeric 'read-through' variant of AChE (AChE-R), is important in conferring protection against Parkinson-like symptoms. Furthermore, intravenous injection with PRX-105 induced a protective gene expression profile in the striatum of the brain.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Nu Skin EVP of global sales takes medical leave
- BIGG Digital Assets to rename as Surge Digital, consolidate shares
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
